Yes. Oral denifanstat 50 mg once daily produced about a 77% mean reduction in inflammatory acne lesions after up to 52 weeks of total exposure. Denifanstat is a once-daily oral fatty-acid synthase inhibitor that reduces sebum-lipid production and targets acne-related inflammation.
The result comes from longer-term follow-up in moderate-to-severe acne vulgaris. It reflects average change, not clearance for every person. Individual results varied around that mean.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How was the 77% reduction measured?
- Did total lesions and overall severity improve?
- Who was studied?
- Can you get denifanstat now?
How was the 77% reduction measured?
The 52-week total included a 12-week parent trial plus up to 40 more weeks of denifanstat in extension trial ASC40-304. According to Dermatology Times, the extension enrolled 240 completers from the 480-patient parent trial ASC40-303 in China extension results.
Improvement was measured against parent-trial baseline. ASC40-304 was open-label with safety as the primary endpoint. It had no concurrent placebo group for efficacy comparison.
Did total lesions and overall severity improve?
Yes. The same long-term regimen produced about a 72% mean reduction in total lesions. About 57% of participants reached Investigator's Global Assessment treatment success.
Those outcomes matter because inflammatory papules and pustules cause pain, redness, and scarring risk. Total count captures blackheads and whiteheads too. According to HCPLive, both lesion measures improved steadily through 52 weeks long-term acne outcomes.
Who was studied?
The trials studied moderate-to-severe acne vulgaris. That means widespread inflamed breakouts, often with nodules and risk of lasting marks.
The parent trial averaged around age 22. Roughly two-thirds to 70% of participants were female, as reported by Managed Healthcare Executive. Results therefore best apply to adolescents and young adults with persistent inflammatory acne.
Can you get denifanstat now?
Denifanstat remains investigational in the United States. It is not an approved prescription acne drug. According to Sagimet Biosciences, the U.S. AURORA Phase 3 trial plans about 800 patients aged 12 and older, with the first patient dosed Oct.
22, 2026 AURORA trial announcement. Through 52 weeks, treatment was generally well tolerated. There were no adverse-event-related permanent discontinuations and no drug-related serious adverse events. Dry skin occurred in 7.1% and dry eye in 5.9%.
- Ask a dermatologist whether a clinical trial could fit your acne severity and age
- Bring a list of past retinoids, benzoyl peroxide, antibiotics, hormonal therapy, and isotretinoin
- Track inflammatory lesion count, pain, new scarring, and dryness at each visit
- Do not change prescribed acne treatment to wait for an investigational drug